ARS Pharmaceuticals, Inc. (SPRY)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | 15,717 | 7,973 | 2,068 | |
| Selling, general and administrative (including related party amounts of 107, 114, 231, and 208, respectively) | 54,312 | 41,104 | 19,281 | |
| Research and development (including related party amounts of 582, 518, 1,245, and 1,245, respectively) | 4,035 | 2,952 | 4,423 | |
| Cost of goods sold (including related party amounts of 866, 0, 1,354, and 0, respectively) | 4,984 | 1,094 | 112 | |
| Total operating expenses | 63,331 | 45,150 | 23,816 | |
| Loss from operations | -47,614 | -37,177 | -21,748 | |
| Other income, net | 2,731 | 3,237 | 2,620 | |
| Net loss | -44,883 | -33,940 | -19,128 | |
| Change in unrealized gains and losses on available-for-sale securities | -118 | -148 | 484 | |
| Comprehensive loss | -45,001 | -34,088 | -18,644 | |
| Earnings per share, basic, total | -0.46 | -0.35 | -0.2 | |
| Earnings per share, diluted, total | -0.46 | -0.35 | -0.2 | |
| Weighted average number of shares outstanding, basic, total | 98,361,771 | 98,060,636 | 97,032,331 | |
| Weighted average number of shares outstanding, diluted, total | 98,361,771 | 98,060,636 | 97,032,331 | |